Russia collaborated with Indian pharmaceuticals major Dr. Reddy’s Laboratories to conduct clinical trials and distribute COVID-19 vaccine Sputnik V.
The Russian Direct Investment Fund (RDIF) CEO Kirill Dmitriev said the collaboration was confirmed on September 16. The RDIF is in talks with Indian regulators to ensure that all the requirements for clinical trials are being met with, he added. Upon regulatory approval in India, the RDIF shall supply Dr. Reddy's 100 million vaccine doses.
The collaboration happened in the backdrop of discussions between Russia's envoy to India, Nikolay Kudashev, and Indian officials to discuss cooperation during the vaccine's joint development and production.
The COVID-19 pandemic has given rise to a lot of potentially dangerous misinformation. For reliable advice on COVID-19 including symptoms, prevention and available treatment, please refer to the World Health Organisation or your national healthcare authority.